Literature DB >> 19217514

Other therapies for reducing low-density lipoprotein cholesterol: medications in development.

Evan A Stein1.   

Abstract

Although the past 30 years have been fruitful and productive in lipid research, from basic science to drug development to demonstration of clinical benefit, cardiovascular disease remains the major cause of mortality and morbidity in industrialized societies. With the rapid industrialization of countries, such as India and China, cardiovascular disease rapidly is becoming the leading cause of global death and disability. Although most of the effective lipid-lowering drugs, the statins, have become generic and inexpensive, there remains a need for effective and safe agents. Hopefully, some of those discussed in this article will fill that need.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217514     DOI: 10.1016/j.ecl.2008.11.011

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  6 in total

Review 1.  The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors:  Anandita Agarwala; Peter Jones; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 2.  The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Authors:  P C Manoria; H K Chopra; S K Parashar; A L Dutta; Brian Pinto; Ajit Mullasari; Samir Prajapati
Journal:  Indian Heart J       Date:  2013-11-25

3.  Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Authors:  Adam E Mullick; Wuxia Fu; Mark J Graham; Richard G Lee; Donna Witchell; Thomas A Bell; Charles P Whipple; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2011-02-22       Impact factor: 5.922

Review 4.  Management of the patient with statin intolerance.

Authors:  Byron F Vandenberg; Jennifer Robinson
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

Review 5.  Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?

Authors:  Anna Raper; Daniel M Kolansky; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

6.  Crystal structure of 9-(4-bromo-but-yl)-9H-fluorene-9-carb-oxy-lic acid.

Authors:  Xu-Yang Zhang; Bing-Ni Liu; Ping-Bao Wang; Deng-Ke Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-09-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.